|
Study population
| |
|
A.
|
Inception cohort (defined in relationship to onset of symptoms)
|
+/−/?
|
|
B.
|
Description of inclusion and exclusion
|
+/?
|
|
C.
|
Description of study population
|
+/?
|
|
Response
| |
|
D.
|
Response >75 %
|
+/−/?
|
|
E.
|
Information about non-responders versus responders
|
+/−/?
|
|
Follow-up (extent and length)
| |
|
F.
|
Prospective data collection
|
+/−/?
|
|
G.
|
Follow-up of at least 6 months
|
+/−/?
|
|
H.
|
Drop-outs/loss to follow-up < 20 %
|
+/−/?
|
|
I.
|
Information completers versus loss to follow-up/drop-outs
|
+/−/?
|
|
Treatment
| |
|
J.
|
Treatment in cohort is fully described/standardised
|
+/−/?
|
|
Outcome
| | |
|
K.
|
Standardised assessment of relevant outcome criteria
|
+/?
|
|
Prognostic factors
| |
|
L.
|
Standardised assessment of patient characteristics and potential clinical prognostic factor(s)
|
+/?
|
|
M.
|
Standardised assessment of potential psychosocial prognostic factor(s)
|
+/?
|
|
Data presentation
| |
|
N.
|
Frequencies of most important outcome measures
|
+/−
|
|
O.
|
Frequencies of most important prognostic factors
|
+/−
|
|
P.
|
Appropriate analysis techniques
|
+/−/?
|
|
Q.
|
Prognostic model is presented
|
+/−/?
|
|
R.
|
Sufficient numbers
|
+/−
|
